Viral vectors have become the most common method for delivering gene therapy; however, pre-existing humoral immunogenicity can potentially render a gene therapy ineffective.
Travis Harrison, PhD - Vice President, Bioassay Solutions, Precision for Medicine
Advertisement
Vice President, Bioassay Solutions, Precision for Medicine
Articles by Travis Harrison, PhD - Vice President, Bioassay Solutions, Precision for Medicine
Advertisement
Latest Updated Articles
Neutralizing Antibody Versus Total Antibody Assays in Gene Therapy Development: Key Considerations for Assessing ImmunogenicityPublished: March 21st 2022 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Guess the Therapy Answer October 23, 2025
2
CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma
3
CGTLive®’s Weekly Rewind – October 24, 2025
4
